Trailing-twelve-month (TTM) revenue is $86.34 Million with a year-over-year growth of +11.21%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $21,202,064 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-03 |
| Q4 FY2025Period ended 2025-12-31 | $22,692,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-06 |
| Q1 FY2026Period ended 2026-03-31 | $21,979,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-01 |
| Q2 FY2026Period ended 2026-06-30 | $20,466,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-07-31 |
| TTM revenue | $86,339,064 |
Current P/S: $1,092,435,180 market capitalization ÷ $86,339,064 TTM revenue = 12.65x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T14:20:10.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $20.47M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T14:22:23.144Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| M R I Compatible I V Infusion Pumps | $9M | N/A | N/A | N/A | N/A | N/A |
| MRI compatible IV infusion pump system | N/A |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| International | N/A | N/A | N/A | $13M | $13M | $13M |
| U | $25M | N/A | N/A |
$86.34M
$86.34 Million
+11.21%
vs. $77.64M a year ago (TTM)
+19.60%
5 Year compound annual growth rate
1 Year
+11.21%
3 Year
+12.97%
5 Year
+19.60%
10 Year
+9.20%
15 Year
N/A
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $83.81M | +$10.57M | +14.43% |
| 2024 | $73.24M | +$7.68M | +11.71% |
| 2023 | $65.56M | +$12.26M | +23.00% |
| 2022 | $53.30M | +$11.49M | +27.48% |
| 2021 | $41.81M | +$10.10M | +31.83% |
| 2020 |
TTM Growth
+11.21%
3-Year CAGR
+12.97%
5-Year CAGR
+19.60%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T14:22:23.144Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| N/A |
| N/A |
| N/A |
| N/A |
| Mri Compatible Patient Vital Signs Monitoring Systems | $10M | N/A | N/A | N/A | N/A | N/A |
|---|
| MRI compatible patient vital signs monitoring systems | N/A | $14M | N/A | N/A | N/A | N/A |
|---|
| MRI Compatible Patient Vital Signs Monitoring Systems | N/A | N/A | $22M | $25M | $24M | $26M |
|---|
| N/A |
| N/A |
| N/A |
| United States | N/A | $33M | N/A | N/A | N/A | N/A |
|---|
| UNITED STATES | N/A | N/A | $44M | $53M | $61M | $71M |
|---|
| $31.72M |
| ($6.80M) |
| (17.65%) |
| 2019 | $38.52M | +$8.08M | +26.54% |
| 2018 | $30.44M | +$7.36M | +31.88% |
| 2017 | $23.08M | ($9.41M) | (28.97%) |
| 2016 | $32.50M | +$902,828 | +2.86% |
